目的 探究大株紅景天注射液聯(lián)合鹽酸曲美他嗪片治療冠心病心力衰竭的臨床療效。方法 選取2012年9月-2016年9月中國(guó)人民解放軍第四五四醫(yī)院心血管內(nèi)科收治的冠心病心力衰竭患者83例作為研究對(duì)象，所有患者在隨機(jī)分組的原則下分為對(duì)照組（41例）和治療組（42例）。對(duì)照組口服鹽酸曲美他嗪片，1片/次，3次/d。治療組在對(duì)照組基礎(chǔ)上靜脈滴注大株紅景天注射液，10 mL加入生理鹽水250 mL中，1次/d。所有患者均治療4周。觀察兩組的臨床療效，比較兩組的心功能指標(biāo)和心衰標(biāo)志物情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為75.61%、95.24%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組左室射血分?jǐn)?shù)（LVEF）明顯升高，而左心室舒張末期內(nèi)徑（LVEDD）和左心房舒張末期內(nèi)徑（LAEDD）明顯下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組N端-前腦利鈉肽（NT-ProBNP）、內(nèi)皮素和去甲腎上腺素水平均顯著下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 大株紅景天注射液聯(lián)合鹽酸曲美他嗪片治療冠心病心力衰竭具有較好的臨床療效，能顯著改善患者的心功能，安全較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical efficacy of Sofren Injection combined with Trimetazidine Hydrochloride Tablets in treatment of heart failure of coronary heart disease. Methods Patients (83 cases) with heart failure of coronary heart disease in Department of Cardiology of No. 454 Hospital of Chinese People's Liberation Army from September 2012 to September 2016 were randomly divided into the control group (41 cases) and the treatment group (42 cases). Patients in the control group were po administered with Trimetazidine Hydrochloride Tablets, 1 tablet/time, three times daily. Patients in the treatment group were iv administered with Sofren Injection on the basis of the control group, 10 mL added into normal saline 250 mL, once daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and cardiac function indexes and heart failure markers in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 75.61% and 95.24%, respectively, and there was difference between two groups (P<0.05). After treatment, the LVEF in two groups were significantly increased, but LVEDD and LAEDD in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of NT-ProBNP, endothelin, and norepinephrine in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Sofren Injection combined with Trimetazidine Hydrochloride Tablets has clinical curative effect in treatment of heart failure of coronary heart disease, and can significantly improve heart function, with good safety, which has a certain clinical application value.